2016
Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population. Journal Of Clinical Oncology 2016, 34: 32-32. DOI: 10.1200/jco.2016.34.7_suppl.32.Peer-Reviewed Original ResearchHigh-risk diseaseOncotype DXRisk diseaseChemotherapy costsODX testingBreast cancerAdjuvant chemotherapyRisk womenPatient outcomesEnd Results-Medicare dataEarly-stage breast cancerER-positive breast cancerReal-world clinical practiceIntermediate-risk womenSEER-Medicare populationLow-risk diseaseHigh-risk womenPositive breast cancerWorld clinical practiceActual patient outcomesTotal Medicare paymentsNCCN guidelinesOverall cohortMultivariable analysisPathologic features
2015
Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer
Dinan MA, Li Y, Zhang Y, Stewart SB, Curtis LH, George DJ, Reed SD. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. Clinical Genitourinary Cancer 2015, 14: 28-37.e2. PMID: 26382223, PMCID: PMC4698191, DOI: 10.1016/j.clgc.2015.07.006.Peer-Reviewed Original ResearchConceptsEnd Results-Medicare dataEnd of lifeProstate cancerOutpatient settingOutpatient useRetrospective analysisMore hospicesLower mean inpatient costsSkilled nursing facility daysIntensive care unit daysIntensive care unit useJudicious careAndrogen deprivation therapyOverall health care costsUse of chemotherapyMean inpatient costsMultiple invasive proceduresHealth care costsSignificant financial burdenDeprivation therapyNoncancer causesICU useSingle strongest predictorUnit daysInpatient costsLongitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer
Robinson TJ, Dinan MA, Li Y, Lee WR, Reed SD. Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. Journal Of Palliative Medicine 2015, 18: 933-939. PMID: 26241733, PMCID: PMC4638209, DOI: 10.1089/jpm.2015.0171.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancer metastasisRadiation therapyTreatment courseProstate cancerBony metastasesEnd Results-Medicare dataRadiation treatmentCancer metastasisCost-effective palliationPalliative radiation therapyPalliative radiation treatmentGeneral patient populationShort treatment courseHospital-based settingStudy inclusion criteriaTotal Medicare paymentsRadiation treatment courseRadiation therapy techniquesLack of evidencePalliative radiationPalliative settingPalliative treatmentClinical benefitPatient population
2013
Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007. Radiology 2013, 267: 807-817. PMID: 23418003, DOI: 10.1148/radiol.12120174.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositron emission tomographyUse of PETMedicare beneficiariesCases of NSCLCPET useDiagnosis of NSCLCEnd Results-Medicare dataMultivariable logistic regression analysisDuke University Health SystemHalf of patientsCell lung cancerExamination 2 monthsMultivariable regression analysisUniversity Health SystemLogistic regression analysisDemographic subgroupsRegression analysisInstitutional review boardNonblack patientsPrimary outcomeFinal cohortSurveillance EpidemiologyLung cancerRetrospective analysis
2012
Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003. Journal Of Clinical Oncology 2012, 30: 2725-2730. PMID: 22753917, DOI: 10.1200/jco.2011.40.4392.Peer-Reviewed Original ResearchConceptsPositron emission tomographyOverall survivalStage migrationMedicare beneficiariesAdvanced diseasePET useEnd Results-Medicare dataEmission tomographyProportion of patientsStage IV diseaseCell lung cancerSelection biasUpstaging of diseaseGreater overall survivalStage-specific survivalStudy criteriaLung cancerSurvival AssociatedImproved outcomesRetrospective analysisStage distributionNSCLCPatientsDiseaseSurvival